Showing 1 - 10 of 116
Persistent link: https://www.econbiz.de/10001674274
Persistent link: https://www.econbiz.de/10001579315
Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at death), hospital utilization, and medical expenditure in Greece during the period 1995 - 2010. The estimates indicate that pharmaceutical innovation increased mean age at death...
Persistent link: https://www.econbiz.de/10010473542
There are two types of prescription drug cost offsets. The first type of cost offset - from prescription drug use - is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. The second type of cost offset - the cost offset...
Persistent link: https://www.econbiz.de/10011987056
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10003977959
We update and extend our previous study of the effect of drug age -- years since FDA approval -- on total medical expenditure, in several respects. The estimates indicate that, in the entire population, a reduction in the age of drugs utilized reduces non-drug expenditure 7.2 times as much as it...
Persistent link: https://www.econbiz.de/10012469718
Persistent link: https://www.econbiz.de/10000940644
Persistent link: https://www.econbiz.de/10001205882
Persistent link: https://www.econbiz.de/10001560563
The nation's spending for prescription drugs has grown dramatically in recent years. Previous studies have shown that the replacement of older drugs by newer, more expensive, drugs is the single most important reason for this increase, but they did not measure how much of the difference between...
Persistent link: https://www.econbiz.de/10001566378